NIPPON-SHOKUBAI
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216286680/en/
Figure 1 Comparison between RO system and FO system (Graphic: Business Wire)
In recent years, water shortage has become a serious problem in the world, and reverse osmosis (hereinafter “RO”) is widely used in the seawater desalination for agricultural and drinking water use and for treatment of industrial water. The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities. While this system enables the acquisition of high quality water, the large amount of electric power consumed by the pressurizing pump is considered an issue (Figure 1).
Meanwhile, the FO system is focused on as a means that will resolve this issue. The FO system utilizes the osmosis, which is a natural process and occurs when liquids of differing solute concentrations are separated by a semi-permeable membrane and water moves by the process of osmosis from the solution of lower concentration to that of higher concentration. In the seawater desalination, the FO system utilizes the difference in solute concentration in seawater and draw solution, and the natural osmotic pressure as a result of the draw solution on one side of a FO membrane (a semi-permeable membrane) to pull / transport fresh water from seawater into the draw solution with everything taking place under low pressure and energy conditions (Figure 1). Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).
Trevi Systems is a company in the United States which was founded in 2010. Key elements of Trevi Systems’ FO system are the use of retrograde thermolytic solute draw solution and recycling of the draw solute back to the FO membrane (Figure 2). Trevi Systems conducted a pilot test to demonstrate the production of fresh water at a volume of 50 m3 per day from seawater in Middle East (the UAE) in 2016, which confirmed that the use of the FO system was able to reduce electric power consumption to about 1/3 compared to that of the RO system.
However, the improvement in the amount of water production is necessary for the widespread utilization of the FO system at full scale, and the improvement in the function of the draw solution as the key component is crucial for realizing this. Nippon Shokubai and Trevi Systems have successfully developed a draw solution with the capability of improving water production by 30% compared with the previous product. This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).
Key achievements of the project include:
- The fresh water recovery ratio from seawater exceeded 65% surpassing commercial RO systems’ capabilities.
- Electrical energy consumption is 1/3 compared with RO systems.
- Competitive Capital Costs: Demonstrated capital costs competitive with existing RO desalination systems.
Trevi Systems is committed to further expanding the NELHA plant’s capabilities, with plans to increase capacity to over 6,000m3/day at the same site, and showcasing the potential for zero liquid discharge (*3) by the use of brine and brine concentration for mineral recovery.
The FO system is under consideration to be introduced for seawater desalination in areas with high demand for water, such as the Middle East, as well as for brine concentration to achieve zero liquid discharge. Nippon Shokubai will make further efforts to improve the performance and functions of the draw solution with a view toward future expansion of the FO system.
*1: About Trevi Systems
Trevi Systems Inc. is California based company who is a pioneer in forward osmosis technology for sustainable and efficient water desalination and brine concentration. With a commitment to innovation and environmental responsibility, Trevi Systems continues to redefine the possibilities in utilizing forward osmosis and pressurized forward osmosis to deliver clean water and other resources from the most challenging wastewaters.
For more information: https://www.trevisystems.com/
*2: FO seawater desalination project in Hawaii
The FO system by Trevi Systems was adopted in the Sun Shot program by the Department of Energy, USA. An experiment will be conducted to demonstrate the desalination of seawater using the solar heat collection facility owned by the Natural Energy Laboratory of the Hawaii Authority (NELHA).
*3: zero liquid discharge (ZLD)
One of water treatment processes intended to reduce wastewater and produce clean water that is suitable for reuse. ZLD systems purify and recycle virtually all wastewater received.
The press release issued by Nippon Shokubai is here.
The press release issued by Trevi Systems is here.
About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is "TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology".
For more information: https://www.shokubai.co.jp/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216286680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
